The accelerated excretion of 2,3,4,7,8-pentachlorodibenzofuran by Cholebine

Takumi Ishida, Yuichi Sakai, Yuji Ishii, Masutaka Furue, Hideyuki Yamada

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

While it has been reported that the blood level of dioxins and polychlorinated biphenyls in humans may be decreased by treatment with colestimide, the effects of the agent are still obscure. To address this issue, we examined the effect of Cholebine, a cholesterol lowering agent containing colestimide as an active ingredient, on the excretion of 2,3,4,7,8-pentachlorodibenzofuran (PenCDF) in rats. In a short term study, male Wistar rats (5 weeks-old) were given chows including 3% Cholebine (PenCDF/Chol group) or control chows (PenCDF group) for 7 days after administration of 14C-labeled PenCDF (0.5 mg/kg body weight, p.o.). On day 1, the fecal excretion of PenCDF in the PenCDF/Chol group was greater by 15% compared to that of the PenCDF group. Although some increases were also observed during day 2 and day 7, Cholebine did not exhibit any marked effect on the fecal excretion of PenCDF. The tissue concentrations of PenCDF at day 7 in the PenCDF/Chol group showed a 20%-30% decrease compared with those of the PenCDF group, except that the level in the brain was comparable between the two groups. The fecal excretion of PenCDF in a long term study (Cholebine treatment for 28 days) demonstrated the same tendency as that of short-term study. However, in long-term study, the Cholebine had no effect on the tissue concentration of PenCDF except for brain. An increase in PenCDF excretion by Cholebine seems to be due to the binding of Cholebine to bile acids as lipid carriers. This is because no binding of Cholebine to 14C-PenCDF was detected. These results suggest that Cholebine has little effect on the reabsorption of dioxin, whereas it reduces substantially the first absorption of dioxin.

Original languageEnglish
Pages (from-to)210-216
Number of pages7
JournalFukuoka igaku zasshi = Hukuoka acta medica
Volume100
Issue number5
Publication statusPublished - Jan 1 2009

Fingerprint

Dioxins
2,3,4,7,8-pentachlorodibenzofuran
cholebine
Polychlorinated Biphenyls
Brain
Bile Acids and Salts
Wistar Rats
Cholesterol
Body Weight
Lipids
Control Groups
colestimide

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

The accelerated excretion of 2,3,4,7,8-pentachlorodibenzofuran by Cholebine. / Ishida, Takumi; Sakai, Yuichi; Ishii, Yuji; Furue, Masutaka; Yamada, Hideyuki.

In: Fukuoka igaku zasshi = Hukuoka acta medica, Vol. 100, No. 5, 01.01.2009, p. 210-216.

Research output: Contribution to journalArticle

@article{2c6bb7e68bee4e8fa08f06f38e674dac,
title = "The accelerated excretion of 2,3,4,7,8-pentachlorodibenzofuran by Cholebine",
abstract = "While it has been reported that the blood level of dioxins and polychlorinated biphenyls in humans may be decreased by treatment with colestimide, the effects of the agent are still obscure. To address this issue, we examined the effect of Cholebine, a cholesterol lowering agent containing colestimide as an active ingredient, on the excretion of 2,3,4,7,8-pentachlorodibenzofuran (PenCDF) in rats. In a short term study, male Wistar rats (5 weeks-old) were given chows including 3{\%} Cholebine (PenCDF/Chol group) or control chows (PenCDF group) for 7 days after administration of 14C-labeled PenCDF (0.5 mg/kg body weight, p.o.). On day 1, the fecal excretion of PenCDF in the PenCDF/Chol group was greater by 15{\%} compared to that of the PenCDF group. Although some increases were also observed during day 2 and day 7, Cholebine did not exhibit any marked effect on the fecal excretion of PenCDF. The tissue concentrations of PenCDF at day 7 in the PenCDF/Chol group showed a 20{\%}-30{\%} decrease compared with those of the PenCDF group, except that the level in the brain was comparable between the two groups. The fecal excretion of PenCDF in a long term study (Cholebine treatment for 28 days) demonstrated the same tendency as that of short-term study. However, in long-term study, the Cholebine had no effect on the tissue concentration of PenCDF except for brain. An increase in PenCDF excretion by Cholebine seems to be due to the binding of Cholebine to bile acids as lipid carriers. This is because no binding of Cholebine to 14C-PenCDF was detected. These results suggest that Cholebine has little effect on the reabsorption of dioxin, whereas it reduces substantially the first absorption of dioxin.",
author = "Takumi Ishida and Yuichi Sakai and Yuji Ishii and Masutaka Furue and Hideyuki Yamada",
year = "2009",
month = "1",
day = "1",
language = "English",
volume = "100",
pages = "210--216",
journal = "Fukuoka Acta Medica",
issn = "0016-254X",
publisher = "福岡医学会",
number = "5",

}

TY - JOUR

T1 - The accelerated excretion of 2,3,4,7,8-pentachlorodibenzofuran by Cholebine

AU - Ishida, Takumi

AU - Sakai, Yuichi

AU - Ishii, Yuji

AU - Furue, Masutaka

AU - Yamada, Hideyuki

PY - 2009/1/1

Y1 - 2009/1/1

N2 - While it has been reported that the blood level of dioxins and polychlorinated biphenyls in humans may be decreased by treatment with colestimide, the effects of the agent are still obscure. To address this issue, we examined the effect of Cholebine, a cholesterol lowering agent containing colestimide as an active ingredient, on the excretion of 2,3,4,7,8-pentachlorodibenzofuran (PenCDF) in rats. In a short term study, male Wistar rats (5 weeks-old) were given chows including 3% Cholebine (PenCDF/Chol group) or control chows (PenCDF group) for 7 days after administration of 14C-labeled PenCDF (0.5 mg/kg body weight, p.o.). On day 1, the fecal excretion of PenCDF in the PenCDF/Chol group was greater by 15% compared to that of the PenCDF group. Although some increases were also observed during day 2 and day 7, Cholebine did not exhibit any marked effect on the fecal excretion of PenCDF. The tissue concentrations of PenCDF at day 7 in the PenCDF/Chol group showed a 20%-30% decrease compared with those of the PenCDF group, except that the level in the brain was comparable between the two groups. The fecal excretion of PenCDF in a long term study (Cholebine treatment for 28 days) demonstrated the same tendency as that of short-term study. However, in long-term study, the Cholebine had no effect on the tissue concentration of PenCDF except for brain. An increase in PenCDF excretion by Cholebine seems to be due to the binding of Cholebine to bile acids as lipid carriers. This is because no binding of Cholebine to 14C-PenCDF was detected. These results suggest that Cholebine has little effect on the reabsorption of dioxin, whereas it reduces substantially the first absorption of dioxin.

AB - While it has been reported that the blood level of dioxins and polychlorinated biphenyls in humans may be decreased by treatment with colestimide, the effects of the agent are still obscure. To address this issue, we examined the effect of Cholebine, a cholesterol lowering agent containing colestimide as an active ingredient, on the excretion of 2,3,4,7,8-pentachlorodibenzofuran (PenCDF) in rats. In a short term study, male Wistar rats (5 weeks-old) were given chows including 3% Cholebine (PenCDF/Chol group) or control chows (PenCDF group) for 7 days after administration of 14C-labeled PenCDF (0.5 mg/kg body weight, p.o.). On day 1, the fecal excretion of PenCDF in the PenCDF/Chol group was greater by 15% compared to that of the PenCDF group. Although some increases were also observed during day 2 and day 7, Cholebine did not exhibit any marked effect on the fecal excretion of PenCDF. The tissue concentrations of PenCDF at day 7 in the PenCDF/Chol group showed a 20%-30% decrease compared with those of the PenCDF group, except that the level in the brain was comparable between the two groups. The fecal excretion of PenCDF in a long term study (Cholebine treatment for 28 days) demonstrated the same tendency as that of short-term study. However, in long-term study, the Cholebine had no effect on the tissue concentration of PenCDF except for brain. An increase in PenCDF excretion by Cholebine seems to be due to the binding of Cholebine to bile acids as lipid carriers. This is because no binding of Cholebine to 14C-PenCDF was detected. These results suggest that Cholebine has little effect on the reabsorption of dioxin, whereas it reduces substantially the first absorption of dioxin.

UR - http://www.scopus.com/inward/record.url?scp=68949125753&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68949125753&partnerID=8YFLogxK

M3 - Article

C2 - 19588851

AN - SCOPUS:68949125753

VL - 100

SP - 210

EP - 216

JO - Fukuoka Acta Medica

JF - Fukuoka Acta Medica

SN - 0016-254X

IS - 5

ER -